Navigation Links
InterMune Announces Start of Phase 1b Trial of ITMN-191
Date:9/26/2007

F) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1a, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 30, 2007 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulat
'/>"/>

SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... New York , August 27, 2014 ... United States  Laparoscopes Market Outlook to ... 2020", provides key market data on the United ... millions of US dollars, volume (in units) and average ... (Rigid Tip Video Laparoscopes and Flexible Tip Video Laparoscopes), ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that a ... Baby Food Eastern Europe 2014 ... Eastern Europe 2014" is a new report by ERC ... Eastern Europe , key segments, features ... report also examines trends which are currently affecting the ...
(Date:8/27/2014)... 2014 Sihuan Pharmaceutical Holdings Group Ltd. ... leading pharmaceutical company with the largest cardio-cerebral vascular ... prescription drug market, today announced the unaudited ... (collectively the "Group") for the six months ended ... HighlightsFor the Six months ended 30 JuneKey Income ...
Breaking Medicine Technology:United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 2United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 3United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 4United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 5Baby Food Eastern Europe 2014 2Baby Food Eastern Europe 2014 3Baby Food Eastern Europe 2014 4Baby Food Eastern Europe 2014 5Baby Food Eastern Europe 2014 6Baby Food Eastern Europe 2014 7Baby Food Eastern Europe 2014 8Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
... SANTA FE, N.M., March 11, 2011 Qforma, an ... appointments of Elna Hamp to Vice President, Business Development ... our clients, business models continue to evolve with the ... to Qforma," said Al Reicheg, Chief Commercial Officer of ...
... Medical International Limited (NYSE: MR ), a leading ... that it will present at the 14th Annual Credit Suisse ... 25th at the Conrad Hotel in Hong Kong. The attendees ... Ms. May Li, Director of Finance and IR; and Ms. ...
Cached Medicine Technology:Qforma Appoints Two New Executives 2
(Date:8/27/2014)... 2014 (HealthDay News) -- A new genetic discovery about ... the bowel disorder, researchers report. The scientists ... how their genes work, and said these changes can ... the possibility of a simple diagnostic test for Crohn,s, ... develops and suggest possible gene targets for new treatments, ...
(Date:8/27/2014)... August, 27, 2014) An experimental drug designed to help ... first treatment for anemia of inflammation, according to results from ... online today in Blood , the Journal ... is a condition that occurs when red blood cells are ... individual has anemia, the body does not get enough oxygen, ...
(Date:8/27/2014)... tested an advanced statistical model to evaluate the ... as published yesterday in Human Genetics . ... in current analyses. Complex diseases like cancer usually ... factors. When many such combinations are studied, identifying ... combinations among affected individuals becomes difficult. In this ...
(Date:8/27/2014)... 2014 The Global and China Maleic ... the current state of the Maleic Anhydride industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
(Date:8/27/2014)... Sugar Manufacturing in Australia ... in global supply and demand, which have contributed to ... industry derives a large share of its revenue from ... dynamics, with supply and prices being determined by larger ... Australian dollar for the majority of the past five ...
Breaking Medicine News(10 mins):Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:Drug represents first potential treatment for common anemia 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4
... the Staying Sharp session on October 4 at the Embassy ... Part of a highly recognized series, the program will emphasize ... industry; factors that predict future cognitive function; and the importance ... The public can reserve free tickets through the toll-free line: ...
... articulating wall mounted arms that offer a space-saving solution without ... environment. , ... Ferndale, MI (PRWEB) ... the next generation in articulating wall-mounted arms. Offering 270 degrees ...
... Oct. 1 Sysmex America, Inc. and its,subsidiary, ... the,company,s new brand logo, said Kazuya Obe, Executive ... The timing of this brand change,corresponds with the ... and,the company,s 40th anniversary. The new logo marks ...
... with,solutions and recommendations drawing on experience working ... PLYMOUTH MEETING, Pa., Oct. 1 Anticipating,the ... Safety and Quality,Improvement Act of 2005, ECRI ... to improve patient care, will preview its ...
... Researchers at the Farber Institute for Neurosciences ... Psychiatry and Human Behavior at Jefferson Medical College ... $3.7 million grant from The National Eye Institute ... macular degeneration (AMD). Barry W. Rovner, M.D., ...
... Rise of cities, risky behavior in west central Africa between ... 1 (HealthDay News) -- The most pervasive global strain of ... a new study claims. , The research, which is ... that HIV began spreading between 1884 and 1924, around the ...
Cached Medicine News:Health News:Enovate IT Announces Fluid - a New Movement in Wall Arms 2Health News:Sysmex Announces Brand Change 2Health News:ECRI Institute Unveils Comprehensive Patient Safety Organization (PSO) Services 2Health News:ECRI Institute Unveils Comprehensive Patient Safety Organization (PSO) Services 3Health News:Jefferson awarded multi-million dollar grant from National Eye Institute for new clinical trial 2Health News:HIV Outbreak Began Decades Earlier Than Thought 2
TSH EIA Thyroid Function 025-BC-1001...
... The anti-TG test kit is a ... microplate format. It is designed for the ... thyroglobulin (TG) in serum or plasma. The ... 1: Calibrators, controls and patient samples are ...
Free Estriol (E3) RIA Reproductive Hormones 024-IDC-1000...
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
Medicine Products: